Taysha Gene Therapies Inc (TSHA) Business Payback Period

Symbol and logo of brand Taysha Gene Therapies Inc (TSHA)

The investment potential of Taysha Gene Therapies (TSHA) is based on the deep outsourcing of all stages of drug development and production to external contractors. The company's P/E range visualizes market expectations, with the indicator standing at -8.30. This model is confirmed by a total dependence on CMOs and CROs, while the current lack of pricing power is offset by the prospect of premium pricing upon FDA approval of the Rett syndrome therapy.

Taysha Gene Therapies (TSHA) - P/E Multiple from 07/04/2022 to 11/18/2026

Comprehensive metric breakdowns and analytics for Taysha Corp (TSHA)

- market price and analyst price targets:
Summary company analysis:TSHA (Taysha Gene Therapies Inc)
Flagship merchandise of Taysha

The P/E ratio determines the market value of a single unit of profit, calculated as the ratio of the current share price to earnings per share. By analyzing the market P/E ratio of Taysha Gene Therapies (TSHA), an investor assesses the degree of overpayment for the business, which is critical for Taysha Gene Therapies (TSHA) due to the high cost of developing Rett syndrome therapy and the protection of intellectual property through patents.

Analysis of competing companies

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio uniQure NV|Price to Earnings Multiple MGTX (MeiraGTx PLC)|Price to Earnings Ratio RGNX (regenxbio.com)|Solid Biosciences Inc. - Price to Earnings Multiple|Price to Earnings Ratio Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Market Cap to Earnings|BNTC - Price to Earnings Ratio|Design Pharma - Market Price to Net Income Ratio|RCKT (Rocket Pharmaceuticals Inc) - Price to Earnings Ratio|4D Molecular Therapeutics (FDMT) - P/E Multiple|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio